|
業務類別
|
Biotechnology |
|
業務概覽
|
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity. |
| 公司地址
| 1599 Industrial Road, San Carlos, CA, USA, 94070 |
| 電話號碼
| +1 650 980-9099 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.biomeafusion.com |
| 員工數量
| 41 |
| Mr. Rainer M. Erdtmann |
Director, President, Chief Operating Officer, Chief Financial Officer and Principal Accounting Officer |
美元 489.60K |
24/03/2026 |
| Dr. Michael J. M. Hitchcock, PhD |
Director and Interim Chief Executive Officer |
美元 486.74K |
27/04/2026 |
|
|
| Mr. Rainer M. Erdtmann |
Director, President, Chief Operating Officer, Chief Financial Officer and Principal Accounting Officer |
24/03/2026 |
| Dr. Eric Aguiar, M.D. |
Lead Independent Director |
27/04/2026 |
| Dr. Elizabeth Faust, PhD |
Independent Director |
27/04/2026 |
| Ms. Sumita Ray, J.D. |
Independent Director |
27/04/2026 |
| Ms. Julianne Averill |
Independent Director |
27/04/2026 |
| Dr. Michael J. M. Hitchcock, PhD |
Director and Interim Chief Executive Officer |
27/04/2026 |
|
|
|
|
